AZD-3161

AZD-3161

AZD-3161 is an investigational pharmaceutical compound developed by AstraZeneca, primarily researched for its potential applications in oncology. It is classified as a small molecule inhibitor targeting specific pathways involved in cancer cell proliferation and survival.

Mechanism of Action

AZD-3161 functions by inhibiting key enzymes involved in the signaling pathways that regulate cell growth and division. Specifically, it targets the PI3K/AKT/mTOR pathway, which is often dysregulated in various types of cancer. By blocking this pathway, AZD-3161 aims to reduce tumor growth and induce apoptosis in cancer cells.

Clinical Development

AZD-3161 is currently undergoing clinical trials to evaluate its efficacy and safety in treating different forms of cancer. The trials are designed to assess its impact on tumor size, progression-free survival, and overall survival rates in patients. Early-phase trials have shown promising results, leading to further investigation in larger, more comprehensive studies.

Pharmacokinetics

The pharmacokinetic profile of AZD-3161 includes its absorption, distribution, metabolism, and excretion characteristics. It is administered orally, and studies have shown that it has a favorable bioavailability. The compound is metabolized primarily in the liver, and its metabolites are excreted through the renal and biliary systems.

Side Effects

As with many targeted cancer therapies, AZD-3161 may cause a range of side effects. Common adverse effects observed in clinical trials include nausea, fatigue, diarrhea, and skin rash. More serious side effects, although less common, may include liver toxicity and hematological abnormalities. Ongoing studies aim to better understand the safety profile of AZD-3161 and manage any potential risks associated with its use.

Future Directions

Research on AZD-3161 continues to explore its potential in combination therapies, where it is used alongside other anticancer agents to enhance therapeutic outcomes. Additionally, studies are investigating its role in overcoming resistance to existing treatments, a significant challenge in oncology.

Also see

• PI3K inhibitors
• Targeted cancer therapy
• Clinical trials
• Oncology

This article is a stub related to pharmacology. You can help WikiMD by expanding it!